AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES

被引：1

作者：

Winthrop, K. ^{[1
]}

Gold, D. ^{[2
]}

Henrohn, D. ^{[3
]}

Wang, L. ^{[4
]}

Shapiro, A. ^{[5
]}

Shi, H. ^{[6
]}

Citera, G. ^{[7
]}

Schulze-Koops, H. ^{[8
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[2] Pfizer Inc, Montreal, PQ, Canada

[3] Pfizer Inc, Sollentuna, Sweden

[4] Pfizer Inc, Groton, CT 06340 USA

[5] Pfizer Inc, Peapack, NJ USA

[6] Pfizer Inc, Collegeville, PA USA

[7] Inst Rehabil Psicofis, Buenos Aires, DF, Argentina

[8] Klinikum Univ Munchen, Munich, Germany

来源：

关键词：

D O I：

10.1136/annrheumdis-2020-eular.1432

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0139

引用

页码：1003 / 1004

页数：2

共 32 条

AGE-BASED (&lt;65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES